ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation

Xu, Hongbei; You, Mingyao; Xiang, Xiang; Zhao, Jun; Yuan, Ping; Chu, Lan; Xie, Chenchen*重庆大学
Oxidative Medicine and Cellular Longevity2022-10-27DOI: 10.1155/2022/3858314
4被引6阅读
引用收藏
分享

摘要

Ischemic stroke exhibits high morbidity, disability, and mortality, and treatments for ischemic stroke are limited despite intensive research. The potent neuroprotective benefits of Epimedium against ischemic stroke have gained lots of interest. Nevertheless, systematic research on the direct role and mechanisms of Epimedium in ischemic stroke is still lacking. Network pharmacology analysis coupled with experimental verification was utilized to systematically evaluate the potential pharmacological mechanism of Epimedium against ischemic stroke. The TCMSP database was used to mine the bioactive ingredients and Epimedium's targets. The DrugBank, OMIM, and GeneCards databases were employed to identify potential targets of ischemic stroke. GO and KEGG pathway analyses were also carried out. The interaction between active components and hub targets was confirmed via molecular docking. An experimental ischemic stroke model was used to evaluate the possible therapeutic mechanism of Epimedium. As a result, 23 bioactive compounds of Epimedium were selected, and 30 hub targets of Epimedium in its function against ischemic stroke were identified, and molecular docking results demonstrated good binding. The IL-17 signaling pathway was revealed as a potentially significant pathway, with the NF-kappa B and MAPK/ERK signaling pathways being involved. Furthermore, in vivo experiments demonstrated that Epimedium treatment could improve neurological function and reduce infarct volume. Additionally, Epimedium reduced the activation of microglia and astrocytes in both the ischemic penumbra of the hippocampus and cerebral cortex following ischemic stroke. Western blot and RT-qPCR analyses demonstrated that Epimedium not only depressed the expression of IL-1 beta, TNF-alpha, IL-6, and IL-4 but also inhibited the NF-kappa B and MAPK/ERK signaling pathways. This study applied network pharmacology and in vivo experiment to explore possible mechanism of Epimedium's role against ischemic stroke, which provides insight into the treatment of ischemic stroke.

学科与关键词

关键词
CEREBRAL-ARTERY OCCLUSIONBRAIN
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Oxidative Medicine and Cellular Longevity
发表日期
2022-10-27
卷期
第 2022 卷
页码
3858314
DOI
10.1155/2022/3858314
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Youth Fund Project [82160242]; National Natural Science regional foundation project [gyfybsky-2021-23]; Basic research project of Guizhou Science and Technology plan (Qiankehe Foundation); Doctoral research start-up fund [82001270]

作者

  • X

    Xu, Hongbei (第一作者)

  • Y

    You, Mingyao

查看全部 7 位作者收起作者
  • X

    Xiang, Xiang

    chongqing univ

  • Z

    Zhao, Jun

  • Y

    Yuan, Ping

  • C

    Chu, Lan

  • X

    Xie, Chenchen (通讯)

    chengdu univ · 2 · chongqing med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417